4Hadziyannis S, Alexopoulou A, Papakonstantinou A, et al. Interferon treatment with or without oral ganeielovir in HBeAg-negative chronic hepatitis B: a randomized study. J Viral Hepat,2000,7 : 235-240.
5Johnson MA, Jenkins JM, Bye C. A study of the pharmacokinetic interaction between lamivudine and alpha interferon. Eur J Clin Pharmacol, 2000,56 : 289-292.
6Korba BE, Cote P, Hornbuckle W, et al. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir Ther,2000,5 : 95-104.
7Mutimer D, Naoumov N, Honkoop P, et al. Combination alphainterferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol,1998, 28:923-929.
8Schalm SW, Heatheote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
9Mutimer D, Dowling D, Cane P, et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir Ther, 2000, 5:273-277.
10Seehofer D, Rayes N, Berg T, et al. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation, 2000, 69: 1739-1742.
4Hong Deng,Jing Dong,Jun Cheng,Kun-Jing Huangfu,Shuang-Shuang Shi,Yuan Hong,Xi-Min Ren,Li Li the Department of Communicable Diseases, the Second Hospital of Xi’an an Jiaotong University, Xi’an 710004, China and the Gene Therapy Research Center, Institute of Infections Diseases, the 302 Hospital of PLA, Beijing 100039, China.Quasispecies groups in the core promoter region of hepatitis B virus[J].Hepatobiliary & Pancreatic Diseases International,2002,1(3):392-396. 被引量：1
